免疫抑制剂对金黄色葡萄球菌血流感染临床表现与结局的影响:两项大型前瞻性队列的倾向评分匹配分析
基于INSTINCT和ISAC两项2006-2015年前瞻性国际多中心队列,3188例SAB患者中309例接受免疫抑制治疗者与309例非免疫抑制者行1:1倾向评分匹配。
要点
- 非激素类免疫抑制剂者晚期并发症风险更高(HR 3.69,95%CI 1.41-9.68)。
核心结论
- 免疫抑制剂整体未与SAB患者总体死亡率升高相关。
- 特定免疫抑制剂如IMOTS者SAB相关晚期并发症风险需进一步研究。
研究设计与样本
- 分析INSTINCT与ISAC两项2006-2015年前瞻性国际多中心队列数据。
- 3188例SAB患者中识别309例免疫抑制治疗者,1:1倾向评分匹配309例非免疫抑制者。
- 采用Cox回归分析总生存,竞争风险分析SAB相关晚期并发症。
- 对激素单药与其他免疫抑制剂(IMOTS)重复上述分析。
主要发现
- 匹配后基线特征均衡;免疫抑制组随访死亡105/309(33.9%),非免疫抑制组94/309(30.4%)。
- IMOTS者原因特异性HR 3.69(95%CI 1.41-9.68)。
临床怎么用
- 对SAB合并免疫抑制患者,总体死亡风险未见显著升高,但仍需警惕晚期并发症。
- 使用非激素类免疫抑制剂者应加强SAB相关晚期并发症监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Staphylococcus aureus bloodstream infection (SAB) is a common, life-threatening infection. The impact of immunosuppressive agents on the outcome of patients with SAB is incompletely understood. METHODS: Data from 2 large prospective, international, multicenter cohort studies (Invasive Staphylococcus aureus Infections Cohort [INSTINCT] and International Staphylococcus aureus Collaboration [ISAC]) between 2006 and 2015 were analyzed. Patients receiving immunosuppressive agents were identified and a 1:1 propensity score-matched analysis was performed to adjust for baseline characteristics of patients. Overall survival and time to SAB-related late complications (SAB relapse, infective endocarditis, osteomyelitis, or other deep-seated manifestations) were analyzed by Cox regression and competing risk analyses, respectively. This approach was then repeated for specific immunosuppressive agents (corticosteroid monotherapy and immunosuppressive agents other than steroids [IMOTS]). RESULTS: Of 3188 analyzed patients, 309 were receiving immunosuppressive treatment according to our definitions and were matched to 309 nonimmunosuppressed patients. After propensity score matching, baseline characteristics were well balanced. In the Cox regression analysis, we observed no significant difference in survival between the 2 groups (death during follow-up: 105/309 [33.9%] immunosuppressed vs 94/309 [30.4%] nonimmunosuppressed; hazard ratio [HR], 1.20 [95% confidence interval {CI}, .84-1.71]). Competing risk analysis showed a cause-specific HR of 1.81 (95% CI, .85-3.87) for SAB-related late complications in patients receiving immunosuppressive agents. The cause-specific HR was higher in patients taking IMOTS (3.69 [95% CI, 1.41-9.68]). CONCLUSIONS: Immunosuppressive agents were not associated with an overall higher mortality. The risk for SAB-related late complications in patients receiving specific immunosuppressive agents such as IMOTS warrants further investigations.
引用
- Camp J, Glaubitz L, Filla T, et al. Impact of Immunosuppressive Agents on Clinical Manifestations and Outcome of Staphylococcus aureus Bloodstream Infection: A Propensity Score-Matched Analysis in 2 Large, Prospectively Evaluated Cohorts. Clin Infect Dis. 2021. PMID: 33914861. doi:10.1093/cid/ciab385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。